Dr Trevor Phillips
Appointment to the Board:
Dr Trevor Phillips was appointed to the hVIVO Board as a Non-Executive Director in June 2017 and subsequently Executive Chairman in November 2017.
Experience and expertise
Trevor has over 30 years of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focussed on airways diseases. Subsequent to joining Vectura in
2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016. Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company, where he was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development, commercial product manufacturing and M&A activity. He led the merger of Critical Therapeutics with Cornerstone BioPharma Holdings. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc). Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986.
He was awarded an MBA from Henley Management College in 1997.
Current external appointments
Trevor is currently Non-Executive Director at Morvus Technology Ltd and Non-Executive Director at NEPeSMO Ltd.